Last updated: January 2, 2025
Sponsor: St. Olavs Hospital
Overall Status: Active - Recruiting
Phase
2
Condition
N/ATreatment
Saline (NaCl 0,9 %) (placebo)
Oxytocin nasal spray
Clinical Study ID
NCT06757517
32672
Ages 18-65 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Patients aged 18 - 65 years, taking benzodiazepines at a daily dose of 20-80 mgdiazepam-equivalent, and requiring inpatient benzodiazepine withdrawal. Includedpatients must consent to participate in the study.
Exclusion
Exclusion Criteria:
- Female patients will be excluded if they are pregnant or are planning to become so,or if they are breast-feeding. Individuals incapable of completing questionnaires orgiving informed consent will be excluded. Patients with concurrent acute medical orpsychiatric illness requiring acute care hospitalization, misuse or dependency ofalcohol or pregabalin/gabapentin will be excluded.
Study Design
Total Participants: 60
Treatment Group(s): 2
Primary Treatment: Saline (NaCl 0,9 %) (placebo)
Phase: 2
Study Start date:
March 01, 2022
Estimated Completion Date:
December 31, 2025
Study Description
Connect with a study center
Blue Cross, Clinic Lade
Trondheim, Trøndelag 7091
NorwayActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.